Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxic...
Ausführliche Beschreibung
Autor*in: |
Liu, Joyce F [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2014 |
---|
Umfang: |
8 |
---|
Übergeordnetes Werk: |
Enthalten in: My - Citovsky, Vitaly ELSEVIER, 2019, London |
---|---|
Übergeordnetes Werk: |
volume:15 ; year:2014 ; number:11 ; pages:1207-1214 ; extent:8 |
Links: |
---|
DOI / URN: |
10.1016/S1470-2045(14)70391-2 |
---|
Katalog-ID: |
ELV022458158 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | ELV022458158 | ||
003 | DE-627 | ||
005 | 20230623163957.0 | ||
007 | cr uuu---uuuuu | ||
008 | 180603s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/S1470-2045(14)70391-2 |2 doi | |
028 | 5 | 2 | |a GBVA2014004000024.pica |
035 | |a (DE-627)ELV022458158 | ||
035 | |a (ELSEVIER)S1470-2045(14)70391-2 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | |a 610 | |
082 | 0 | 4 | |a 610 |q DE-600 |
082 | 0 | 4 | |a 570 |q VZ |
084 | |a BIODIV |q DE-30 |2 fid | ||
084 | |a 35.70 |2 bkl | ||
084 | |a 42.12 |2 bkl | ||
100 | 1 | |a Liu, Joyce F |e verfasserin |4 aut | |
245 | 1 | 0 | |a Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
264 | 1 | |c 2014 | |
300 | |a 8 | ||
336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
337 | |a nicht spezifiziert |b z |2 rdamedia | ||
338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
520 | |a Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. | ||
700 | 1 | |a Barry, William T |4 oth | |
700 | 1 | |a Birrer, Michael |4 oth | |
700 | 1 | |a Lee, Jung-Min |4 oth | |
700 | 1 | |a Buckanovich, Ronald J |4 oth | |
700 | 1 | |a Fleming, Gini F |4 oth | |
700 | 1 | |a Rimel, BJ |4 oth | |
700 | 1 | |a Buss, Mary K |4 oth | |
700 | 1 | |a Nattam, Sreenivasa |4 oth | |
700 | 1 | |a Hurteau, Jean |4 oth | |
700 | 1 | |a Luo, Weixiu |4 oth | |
700 | 1 | |a Quy, Philippa |4 oth | |
700 | 1 | |a Whalen, Christin |4 oth | |
700 | 1 | |a Obermayer, Lisa |4 oth | |
700 | 1 | |a Lee, Hang |4 oth | |
700 | 1 | |a Winer, Eric P |4 oth | |
700 | 1 | |a Kohn, Elise C |4 oth | |
700 | 1 | |a Ivy, S Percy |4 oth | |
700 | 1 | |a Matulonis, Ursula A |4 oth | |
773 | 0 | 8 | |i Enthalten in |n The Lancet Publ. Group |a Citovsky, Vitaly ELSEVIER |t My |d 2019 |g London |w (DE-627)ELV003173852 |
773 | 1 | 8 | |g volume:15 |g year:2014 |g number:11 |g pages:1207-1214 |g extent:8 |
856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(14)70391-2 |3 Volltext |
912 | |a GBV_USEFLAG_U | ||
912 | |a GBV_ELV | ||
912 | |a SYSFLAG_U | ||
912 | |a FID-BIODIV | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 35.70 |j Biochemie: Allgemeines |q VZ |
936 | b | k | |a 42.12 |j Biophysik |q VZ |
951 | |a AR | ||
952 | |d 15 |j 2014 |e 11 |h 1207-1214 |g 8 | ||
953 | |2 045F |a 610 |
author_variant |
j f l jf jfl |
---|---|
matchkey_str |
liujoycefbarrywilliamtbirrermichaelleeju:2014----:obntocdrnbnoaaivruoaaiaoeowmniheurnpaiusniiev |
hierarchy_sort_str |
2014 |
bklnumber |
35.70 42.12 |
publishDate |
2014 |
allfields |
10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610 |
spelling |
10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610 |
allfields_unstemmed |
10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610 |
allfieldsGer |
10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610 |
allfieldsSound |
10.1016/S1470-2045(14)70391-2 doi GBVA2014004000024.pica (DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Liu, Joyce F verfasserin aut Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study 2014 8 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. Barry, William T oth Birrer, Michael oth Lee, Jung-Min oth Buckanovich, Ronald J oth Fleming, Gini F oth Rimel, BJ oth Buss, Mary K oth Nattam, Sreenivasa oth Hurteau, Jean oth Luo, Weixiu oth Quy, Philippa oth Whalen, Christin oth Obermayer, Lisa oth Lee, Hang oth Winer, Eric P oth Kohn, Elise C oth Ivy, S Percy oth Matulonis, Ursula A oth Enthalten in The Lancet Publ. Group Citovsky, Vitaly ELSEVIER My 2019 London (DE-627)ELV003173852 volume:15 year:2014 number:11 pages:1207-1214 extent:8 https://doi.org/10.1016/S1470-2045(14)70391-2 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ AR 15 2014 11 1207-1214 8 045F 610 |
language |
English |
source |
Enthalten in My London volume:15 year:2014 number:11 pages:1207-1214 extent:8 |
sourceStr |
Enthalten in My London volume:15 year:2014 number:11 pages:1207-1214 extent:8 |
format_phy_str_mv |
Article |
bklname |
Biochemie: Allgemeines Biophysik |
institution |
findex.gbv.de |
dewey-raw |
610 |
isfreeaccess_bool |
false |
container_title |
My |
authorswithroles_txt_mv |
Liu, Joyce F @@aut@@ Barry, William T @@oth@@ Birrer, Michael @@oth@@ Lee, Jung-Min @@oth@@ Buckanovich, Ronald J @@oth@@ Fleming, Gini F @@oth@@ Rimel, BJ @@oth@@ Buss, Mary K @@oth@@ Nattam, Sreenivasa @@oth@@ Hurteau, Jean @@oth@@ Luo, Weixiu @@oth@@ Quy, Philippa @@oth@@ Whalen, Christin @@oth@@ Obermayer, Lisa @@oth@@ Lee, Hang @@oth@@ Winer, Eric P @@oth@@ Kohn, Elise C @@oth@@ Ivy, S Percy @@oth@@ Matulonis, Ursula A @@oth@@ |
publishDateDaySort_date |
2014-01-01T00:00:00Z |
hierarchy_top_id |
ELV003173852 |
dewey-sort |
3610 |
id |
ELV022458158 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022458158</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623163957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)70391-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022458158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)70391-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, Joyce F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barry, William T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birrer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jung-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckanovich, Ronald J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fleming, Gini F</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimel, BJ</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buss, Mary K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nattam, Sreenivasa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurteau, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luo, Weixiu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quy, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whalen, Christin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obermayer, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Hang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winer, Eric P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohn, Elise C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ivy, S Percy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matulonis, Ursula A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1207-1214</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)70391-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">1207-1214</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
author |
Liu, Joyce F |
spellingShingle |
Liu, Joyce F ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
authorStr |
Liu, Joyce F |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003173852 |
format |
electronic Article |
dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
delete_txt_mv |
keep |
author_role |
aut |
collection |
elsevier |
remote_str |
true |
illustrated |
Not Illustrated |
topic_title |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
topic |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_unstemmed |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
topic_browse |
ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
zu |
author2_variant |
w t b wt wtb m b mb j m l jml r j b rj rjb g f f gf gff b r br m k b mk mkb s n sn j h jh w l wl p q pq c w cw l o lo h l hl e p w ep epw e c k ec eck s p i sp spi u a m ua uam |
hierarchy_parent_title |
My |
hierarchy_parent_id |
ELV003173852 |
dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
hierarchy_top_title |
My |
isfreeaccess_txt |
false |
familylinks_str_mv |
(DE-627)ELV003173852 |
title |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
ctrlnum |
(DE-627)ELV022458158 (ELSEVIER)S1470-2045(14)70391-2 |
title_full |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
author_sort |
Liu, Joyce F |
journal |
My |
journalStr |
My |
lang_code |
eng |
isOA_bool |
false |
dewey-hundreds |
600 - Technology 500 - Science |
recordtype |
marc |
publishDateSort |
2014 |
contenttype_str_mv |
zzz |
container_start_page |
1207 |
author_browse |
Liu, Joyce F |
container_volume |
15 |
physical |
8 |
class |
610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl |
format_se |
Elektronische Aufsätze |
author-letter |
Liu, Joyce F |
doi_str_mv |
10.1016/S1470-2045(14)70391-2 |
dewey-full |
610 570 |
title_sort |
combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
title_auth |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
abstract |
Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. |
abstractGer |
Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. |
abstract_unstemmed |
Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer. |
collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA |
container_issue |
11 |
title_short |
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study |
url |
https://doi.org/10.1016/S1470-2045(14)70391-2 |
remote_bool |
true |
author2 |
Barry, William T Birrer, Michael Lee, Jung-Min Buckanovich, Ronald J Fleming, Gini F Rimel, BJ Buss, Mary K Nattam, Sreenivasa Hurteau, Jean Luo, Weixiu Quy, Philippa Whalen, Christin Obermayer, Lisa Lee, Hang Winer, Eric P Kohn, Elise C Ivy, S Percy Matulonis, Ursula A |
author2Str |
Barry, William T Birrer, Michael Lee, Jung-Min Buckanovich, Ronald J Fleming, Gini F Rimel, BJ Buss, Mary K Nattam, Sreenivasa Hurteau, Jean Luo, Weixiu Quy, Philippa Whalen, Christin Obermayer, Lisa Lee, Hang Winer, Eric P Kohn, Elise C Ivy, S Percy Matulonis, Ursula A |
ppnlink |
ELV003173852 |
mediatype_str_mv |
z |
isOA_txt |
false |
hochschulschrift_bool |
false |
author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
doi_str |
10.1016/S1470-2045(14)70391-2 |
up_date |
2024-07-06T22:02:22.136Z |
_version_ |
1803868797284646912 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV022458158</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623163957.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1470-2045(14)70391-2</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014004000024.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV022458158</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1470-2045(14)70391-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Liu, Joyce F</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an anti-angiogenic agent with activity against VEGF receptor (VEGFR) 1, VEGFR2, and VEGFR3. Both oral agents have antitumour activity in women with recurrent ovarian cancer, and their combination was active and had manageable toxicities in a phase 1 trial. We investigated whether this combination could improve progression-free survival (PFS) compared with olaparib monotherapy in women with recurrent platinum-sensitive ovarian cancer.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Barry, William T</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Birrer, Michael</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Jung-Min</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buckanovich, Ronald J</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fleming, Gini F</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimel, BJ</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Buss, Mary K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nattam, Sreenivasa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hurteau, Jean</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Luo, Weixiu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quy, Philippa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Whalen, Christin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obermayer, Lisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Hang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Winer, Eric P</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kohn, Elise C</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ivy, S Percy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Matulonis, Ursula A</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">The Lancet Publ. Group</subfield><subfield code="a">Citovsky, Vitaly ELSEVIER</subfield><subfield code="t">My</subfield><subfield code="d">2019</subfield><subfield code="g">London</subfield><subfield code="w">(DE-627)ELV003173852</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1207-1214</subfield><subfield code="g">extent:8</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1470-2045(14)70391-2</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2014</subfield><subfield code="e">11</subfield><subfield code="h">1207-1214</subfield><subfield code="g">8</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
score |
7.398568 |